Q: Recent announcement " Reliq Health Technologies Announces Release of iUGO Care v.2019 and Key Additions to the Management Team" and nice pop in share value this last week.
Do you see a speculative opportunity here and would your appreciate your thoughts on the company considering recent developments. Thanks John
Q: The company sold roughly 50% of it's stake in Peanuts for over $300,0000,000 cdn . That mean it still has an asset worth 300,000,000 at the very least. That works out to a value of $3/share just for the Peanuts asset. Can you tell me where in the Assets category of their balance sheet that this asset would be included in? Is it intangibles or library content or something else? Thanks.
Q: BSM announced so-so eps and revs but seems to be making progress migrating from a hardware- to a software/analytics-centric value proposition (which should also improve margins.) Your take?
Q: I suspect this company is not followed by 5i research as it does not make money yet. I just wanted to know if you have heard of this company (It's headquarter out of Vancouver) and is there anything about this company that you can share?
Q: Hi 5i:
What do you think about Assure at this point? I have been patient with a small position despite the suggestion just to sell and move on to something untroubled, just to see what would happen and because it actually seemed like it had an interesting business. The problems they had seem to be getting resolved. The share price has been relatively stable for a while now with the odd uptick recently. Is there enough going on there to justify my continuing to hold or would you still say no reason to stick around? Thanks!
Q: What is 5i's thoughts about Quorum Information Technologies and the Auto Canada agreement for its subsidiary Dealermine? Quorum seems to have a lot of good things happening, growing quickly from recent acquisitions, lots of recurring revenue and two new analysts picking up coverage with buy recommendations.
Q: Hello! Magellan Aerospace has popped up on one of my value screens. As far as key value ratios go (P/E, P/B, P/S, D/E etc.) it looks promising. Profitability and Management Effectiveness ratios vis-a-vis its competitive set look decent, as does the positive analyst coverage. Insider buying in past year is negligible, however. I'd appreciate hearing your take.